Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Evolutionary
100%
Novel Treatments
100%
Collateral Sensitivity
100%
Drug Resistance
50%
ALK Inhibitor
50%
ALK-TKI
50%
In Cancer
33%
Targeted Therapy
33%
Novel Targeted Therapy
33%
Drug Holiday
33%
EML4-ALK
33%
ALK-positive Lung Cancer
33%
Cancer Cell Lines
16%
Clinically Significant
16%
Treatment Options
16%
Fusion Protein
16%
Cytotoxic Therapy
16%
Sensitivity Analysis
16%
Anticancer Agents
16%
Cancer Therapy
16%
Dynamic Process
16%
Dynamic Pattern
16%
Drug Sensitivity
16%
Sensitivity to Change
16%
Inhibitor Resistant
16%
Highly Dynamic
16%
Cross-resistance
16%
Resistant Cells
16%
Further Treatment
16%
Varying Length
16%
Second-line Agents
16%
Evolved Resistance
16%
Inhibitor Sensitivity
16%
Cross-sensitivity
16%
Resistant Cell Lines
16%
Resistance Evolution
16%
Resistance Sensitivity
16%
Hsp90 Inhibitor
16%
ALK-rearranged
16%
Resistance to Targeted Therapy
16%
Oncogenic Driver Gene
16%
Cycling Holidays
16%
Drug Cycling
16%
TKI Therapy
16%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Targeted Therapy
100%
ALK Inhibitor
60%
Drug Holiday
40%
Drug Resistance
40%
Lung Cancer
20%
Cytotoxic Chemotherapy
20%
Anticarcinogen
20%
Carcinogenesis
20%
Cancer Therapy
20%
Hsp90 Inhibitor
20%
Drug Sensitivity
20%
Cross Resistance
20%
Chimeric Protein
20%
Cross Allergy
20%
Drug Resistance in Cancer
20%
Resistant Cell Line
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Anaplastic Lymphoma Kinase Inhibitor
75%
Drug Resistance
75%
Malignant Neoplasm
50%
Drug Holiday
50%
Cytotoxic Chemotherapy
25%
Lung Cancer
25%
Anticarcinogen
25%
Chimeric Protein
25%
Heat Shock Protein 90 Inhibitor
25%
Cross Allergy
25%
Carcinogenesis
25%
Cross-Resistance
25%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
EML4
66%
Solution and Solubility
33%
Hsp90 Inhibitor
33%
Anticancer
33%
Drug Sensitivity
33%
Cross Resistance
33%
Carcinogenesis
33%
Chimeric Protein
33%